{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:40:04Z","timestamp":1751431204050,"version":"3.41.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04785-6","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:05:52Z","timestamp":1751429152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trial"],"prefix":"10.1007","volume":"95","author":[{"given":"Yizhe","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Marbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Attanasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atalanta","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopal","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"16","key":"4785_CR1","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.2022017423","volume":"141","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Mora B (2023) Myelofibrosis Blood 141(16):1954\u20131970. https:\/\/doi.org\/10.1182\/blood.2022017423","journal-title":"Myelofibrosis Blood"},{"issue":"5","key":"4785_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A (2023) Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(5):801\u2013821. https:\/\/doi.org\/10.1002\/ajh.26857","journal-title":"Am J Hematol"},{"key":"4785_CR3","doi-asserted-by":"publisher","first-page":"484903","DOI":"10.1155\/2013\/484903","volume":"2013","author":"J Murakami","year":"2013","unstructured":"Murakami J, Shimizu Y (2013) Hepatic manifestations in hematological disorders. Int J Hepatol 2013:484903. https:\/\/doi.org\/10.1155\/2013\/484903","journal-title":"Int J Hepatol"},{"issue":"13","key":"4785_CR4","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood 113(13):2895\u20132901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"issue":"8","key":"4785_CR5","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"DAC Fisher","year":"2019","unstructured":"Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, Allen MJ, Malkova ON, Oh ST (2019) Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling. Leukemia 33(8):1978\u20131995. https:\/\/doi.org\/10.1038\/s41375-019-0379-y","journal-title":"Leukemia"},{"issue":"4","key":"4785_CR6","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1038\/bcj.2017.34","volume":"7","author":"D Barraco","year":"2017","unstructured":"Barraco D, Mudireddy M, Shah S, Hanson CA, Ketterling RP, Gangat N, Pardanani A, Tefferi A (2017) Liver function test abnormalities and their clinical relevance in primary myelofibrosis. Blood Cancer J 7(4):e557. https:\/\/doi.org\/10.1038\/bcj.2017.34","journal-title":"Blood Cancer J"},{"key":"4785_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3294046","author":"D Tremblay","year":"2019","unstructured":"Tremblay D, Putra J, Vogel A, Winters A, Hoffman R, Schiano TD, Fiel MI, Mascarenhas JO (2019) The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib. Case Rep Hematol. https:\/\/doi.org\/10.1155\/2019\/3294046","journal-title":"Case Rep Hematol"},{"key":"4785_CR8","unstructured":"Bristol Myers Squibb (2024) (July Inrebic\u00ae (fedratinib) package insert. https:\/\/packageinserts.bms.com\/pi\/pi_inrebic.pdf. Accessed August 2024"},{"key":"4785_CR9","unstructured":"Bristol Myers Squibb (2024) (May Inrebic\u00ae (fedratinib) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inrebic-epar-product-information_en.pdf. Accessed August 2024"},{"issue":"8","key":"4785_CR10","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1038\/bcj.2015.63","volume":"5","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M (2015) A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J 5(8):e335. https:\/\/doi.org\/10.1038\/bcj.2015.63","journal-title":"Blood Cancer J"},{"issue":"7","key":"4785_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29(7):789\u2013796. https:\/\/doi.org\/10.1200\/JCO.2010.32.8021","journal-title":"J Clin Oncol"},{"issue":"4","key":"4785_CR12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00280-019-03929-9","volume":"84","author":"K Ogasawara","year":"2019","unstructured":"Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y (2019) Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. Cancer Chemother Pharmacol 84(4):891\u2013898. https:\/\/doi.org\/10.1007\/s00280-019-03929-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4785_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/jcph.218","volume":"54","author":"M Zhang","year":"2014","unstructured":"Zhang M, Xu CR, Shamiyeh E, Liu F, Yin JY, von Moltke LL, Smith WB (2014) A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. J Clin Pharmacol 54(4):415\u2013421. https:\/\/doi.org\/10.1002\/jcph.218","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4785_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cpdd.161","volume":"4","author":"M Zhang","year":"2015","unstructured":"Zhang M, Xu C, Ma L, Shamiyeh E, Yin J, von Moltke LL, Smith WB (2015) Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): results from two phase I studies in healthy volunteers. Clin Pharmacol Drug Dev 4(4):315\u2013321. https:\/\/doi.org\/10.1002\/cpdd.161","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4785_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70118","author":"Y Chen","year":"2025","unstructured":"Chen Y, Li Y, Xue Y et al (2025) Exposure\u2013response relationship of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Clin Pharmacol. https:\/\/doi.org\/10.1002\/bcp.70118","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"4785_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00280-020-04121-0","volume":"86","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, Xu C, Kanamaluru V, Siebers N, Surapaneni S, Ridoux L, Palmisano M, Krishna G (2020) Excretion balance and pharmacokinetics following a single oral dose of [(14)C]-fedratinib in healthy subjects. Cancer Chemother Pharmacol 86(2):307\u2013314. https:\/\/doi.org\/10.1007\/s00280-020-04121-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"4785_CR17","unstructured":"CTI BioPharma Corp (2023) Vonjo\u00ae (pacritinib) prescribing information. https:\/\/www.ctibiopharma.com\/wp-content\/uploads\/2022\/03\/VONJO_PI_02-2022.pdf. Accessed Apr 2024"},{"issue":"4","key":"4785_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/jcph.1050","volume":"58","author":"Y Xin","year":"2018","unstructured":"Xin Y, Kawashima J, Weng W, Kwan E, Tarnowski T, Silverman JA (2018) Pharmacokinetics and safety of momelotinib in subjects with hepatic or renal impairment. J Clin Pharmacol 58(4):522\u2013532. https:\/\/doi.org\/10.1002\/jcph.1050","journal-title":"J Clin Pharmacol"},{"key":"4785_CR19","unstructured":"European Medicines Agency (2005) Guidelines on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function"},{"issue":"2","key":"4785_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/cpdd.336","volume":"6","author":"AH Talal","year":"2017","unstructured":"Talal AH, Venuto CS, Younis I (2017) Assessment of hepatic impairment and implications for pharmacokinetics of substance use treatment. Clin Pharmacol Drug Dev 6(2):206\u2013212. https:\/\/doi.org\/10.1002\/cpdd.336","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4785_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.6051","author":"H Patel","year":"2004","unstructured":"Patel H, Egorin MJ, Remick SC, Mulkerin D, Takimoto CHM, Doroshow JH, Potter D, Ivy SP, Murgo AJ, Ramanathan RK (2004) Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2004.22.90140.6051","journal-title":"J Clin Oncol"},{"issue":"6","key":"4785_CR22","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00280-020-04084-2","volume":"85","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, Smith WB, Xu C, Yin J, Palmisano M, Krishna G (2020) Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment. Cancer Chemother Pharmacol 85(6):1109\u20131117. https:\/\/doi.org\/10.1007\/s00280-020-04084-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4785_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40262-017-0560-2","volume":"57","author":"Y Horsmans","year":"2018","unstructured":"Horsmans Y, Zhou J, Liudmila M, Golor G, Shibolet O, Quinlan M, Emotte C, Boss H, Castro H, Sellami D, Preston RA (2018) Effects of mild to severe hepatic impairment on the pharmacokinetics of sonidegib: A multicenter, Open-Label, Parallel-Group study. Clin Pharmacokinet 57(3):345\u2013354. https:\/\/doi.org\/10.1007\/s40262-017-0560-2","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4785_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2125.2012.04173.x","volume":"74","author":"U Graefe-Mody","year":"2012","unstructured":"Graefe-Mody U, Rose P, Retlich S, Ring A, Waldhauser L, Cinca R, Woerle HJ (2012) Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol 74(1):75\u201385. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04173.x","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"4785_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/019262339502300203","volume":"23","author":"LZ Benet","year":"1995","unstructured":"Benet LZ, Zia-Amirhosseini P (1995) Basic principles of pharmacokinetics. Toxicol Pathol 23(2):115\u2013123. https:\/\/doi.org\/10.1177\/019262339502300203","journal-title":"Toxicol Pathol"},{"issue":"8","key":"4785_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00003088-200847080-00003","volume":"47","author":"S Mallikaarjun","year":"2008","unstructured":"Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL (2008) Effects of hepatic or renal impairment on the pharmacokinetics of Aripiprazole. Clin Pharmacokinet 47(8):533\u2013542. https:\/\/doi.org\/10.2165\/00003088-200847080-00003","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4785_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/2049936113519089","volume":"2","author":"FV Bupsilondingen","year":"2014","unstructured":"Bupsilondingen FV, Gonzalez D, Tucker AN, Derendorf H (2014) Relevance of liver failure for Anti-Infective agents: from Pharmacokinetic alterations to dosage adjustments. Ther Adv Infect Dis 2(1):17\u201342. https:\/\/doi.org\/10.1177\/2049936113519089","journal-title":"Ther Adv Infect Dis"},{"issue":"1","key":"4785_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00003088-199834010-00002","volume":"34","author":"BM Power","year":"1998","unstructured":"Power BM, Forbes AM, van Heerden PV, Ilett KF (1998) Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 34(1):25\u201356. https:\/\/doi.org\/10.2165\/00003088-199834010-00002","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"4785_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1081\/dmr-100104402","volume":"33","author":"ZH Israili","year":"2001","unstructured":"Israili ZH, Dayton PG (2001) Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 33(2):161\u2013235. https:\/\/doi.org\/10.1081\/dmr-100104402","journal-title":"Drug Metab Rev"},{"issue":"12","key":"4785_CR30","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64(12):1147\u20131161. https:\/\/doi.org\/10.1007\/s00228-008-0553-z","journal-title":"Eur J Clin Pharmacol"},{"key":"4785_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/B978-0-12-411602-3.00055-X","volume-title":"Chronic renal disease","author":"AW Dreisbach","year":"2015","unstructured":"Dreisbach AW, Flessner MF (2015) Chap. 55 - Drug metabolism and chronic kidney disease. In: Kimmel PL, Rosenberg ME (eds) Chronic renal disease. Academic, San Diego, pp 674\u2013681. doi:https:\/\/doi.org\/10.1016\/B978-0-12-411602-3.00055-X"},{"issue":"1","key":"4785_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/cts.13428","volume":"16","author":"P Ravenstijn","year":"2023","unstructured":"Ravenstijn P, Chetty M, Manchandani P, Elmeliegy M, Qosa H, Younis I (2023) Design and conduct considerations for studies in patients with hepatic impairment. Clin Transl Sci 16(1):50\u201361. https:\/\/doi.org\/10.1111\/cts.13428","journal-title":"Clin Transl Sci"},{"issue":"1","key":"4785_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jcph.1702","volume":"61","author":"M Elmeliegy","year":"2021","unstructured":"Elmeliegy M, Yang DZ, Salama E, Parivar K, Wang DD (2021) Discordance between Child-Pugh and National Cancer Institute classifications for hepatic dysfunction: implications on dosing recommendations for oncology compounds. J Clin Pharmacol 61(1):105\u2013115. https:\/\/doi.org\/10.1002\/jcph.1702","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4785_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/cpdd.847","volume":"10","author":"S Cheeti","year":"2021","unstructured":"Cheeti S, Deng Y, Chang I, Georgescu I, Templeton I, Choong N, Cheung KWK, Girish S, Musib L (2021) Effect of hepatic impairment on Cobimetinib pharmacokinetics: the complex interplay between physiological changes and drug characteristics. Clin Pharmacol Drug Dev 10(2):144\u2013152. https:\/\/doi.org\/10.1002\/cpdd.847","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"4785_CR35","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03762.x","volume":"70","author":"A Flint","year":"2010","unstructured":"Flint A, Nazzal K, Jagielski P, Hindsberger C, Zdravkovic M (2010) Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol 70(6):807\u2013814. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03762.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"4785_CR36","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1365-2125.1984.tb02525.x","volume":"18","author":"J Barre","year":"1984","unstructured":"Barre J, Houin G, Rosenbaum J, Zini R, Dhumeaux D, Tillement JP (1984) Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding. Br J Clin Pharmacol 18(4):652\u2013653. https:\/\/doi.org\/10.1111\/j.1365-2125.1984.tb02525.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4785_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/cpdd.77","volume":"3","author":"X Chen","year":"2014","unstructured":"Chen X, Shi JG, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, Punwani NG, Williams WV, Yeleswaram S (2014) Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients. Clin Pharmacol Drug Dev 3(1):34\u201342. https:\/\/doi.org\/10.1002\/cpdd.77","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4785_CR38","unstructured":"Incyte Jakafi\u00ae (2023) (ruxolitinib) prescribing information. https:\/\/www.jakafi.com\/pdf\/prescribing-information.pdf. Accessed Apr 2024"},{"key":"4785_CR39","unstructured":"US Federal Drug Administration (2003) Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04785-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04785-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04785-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:05:55Z","timestamp":1751429155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04785-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4785"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04785-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yizhe Chen, Mark Thomas, Michael Thomas, Bing He, and Ken Ogasawara are employees of and stockholders in Bristol Myers Squibb. Massimo Attaansio, Gopal Krishna and Atalanta Ghosh are stockholders in Bristol Myers Squibb. The Thomas Marbury is an employee of and stockholder in Orlando Clinical Research Center. William B. Smith is an employee of AMR-Clinical. Other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}